Biological standardization of bevacizumab: impact on global harmonization of potency assessment

Biosimilars/Research | Posted 21/01/2022 comments 0
03 AA010722

Bevacizumab is a humanized monoclonal antibody (mAb) targeting vascular endothelial growth factor (VEGF), which causes excessive growth of new blood vessels from pre-existing ones in the form of an...

More >
LATIN AMERICAN FORUM MOST READ
Clinical Trials 2 V13K29
Differences in clinical studies and pharmacovigilance of biological drugs in Latin America
Posted 14/01/2022

Clinical studies are trials conducted in humans to test the efficacy of new drugs, devi...

Etanercept V14H14
Etanercept biosimilars delayed until 2029 in US
Posted 14/01/2022

Yet another patent challenge to Amgen’s originator etanercept, Enbrel, has been denied...

Bevacizumab 2 V14f01
China approves three bevacizumab copy biologicals
Posted 10/12/2021

China’s National Medical Products Administration (NMPA), formerly the China Food and Dr...

Home/Non‐Biological Complex Drugs
Liposome V15L11

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...

More >